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ABSTRACT  21 
 22 
Objective 23 
Evaluation of a protocol of total intraluminal occlusion of Baerveldt shunts and its effects on 24 
early postoperative IOP control and hypotony related complications. 25 
Design 26 
Non-comparative, prospective, interventional study.  27 
Participants 28 
Glaucoma patients were recruited to undergo Baerveldt shunt surgery. A total of 116 eyes of 112 29 
patients were enrolled.  30 
Intervention 31 
During shunt implantation, aqueous outflow was restricted using an intraluminal occluding stent 32 
inserted through the entire tube length, with and without external ligation, to halt aqueous flow. 33 
Postoperatively, eyes underwent ligature laser suture lysis and partial or complete stent removals, 34 
at predetermined time intervals. 35 
Main outcome measure 36 
Loss of postoperative IOP control, categorized as transient or persistent hypotony (IOP≤5 37 
mmHg) or hypertony (IOP>21 mmHg). Patients were followed up for one year. 38 
Results 39 
Preoperatively median IOP was 23 mmHg (mean 26 mmHg, SD 12 mmHg), median number of 40 
glaucoma medications was 3.0 (mean 3.0, SD 1.2). During year one, laser suture lysis was 41 
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performed in 30 eyes (26%) and stent removal in 93 eyes (80%), (23 partial; 70 complete). There 42 
was one case of transient hypotony, no cases of persistent hypotony, 10 of transient hypertony 43 
and three of persistent hypertony. Nine eyes had IOP ≤5 mmHg at one or more time points and 44 
hypotony related complications occurred in 8 eyes (7%). At one year, median IOP was 12 mmHg 45 
(mean 13 mmHg, SD 4 mmHg) with a median of 1.0 glaucoma medications (mean 1.1, SD 1.3). 46 
The cumulative probability of failure during the first 12 months follow-up was 6% (n=7). Overall 47 
postoperative complications occurred in 11 eyes (9%). 48 
Conclusion 49 
The surgical and postoperative protocol resulted in controlled, step-wise reductions of IOP with 50 
low rates of hypotony and related complications. 51 
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INTRODUCTION  52 
Traditionally, aqueous shunts have been reserved for patients with recalcitrant glaucoma or for 53 
those in whom previous filtration surgery had failed.1,2 The Tube Versus Trabeculectomy (TVT) 54 
study highlighted the greater efficacy of shunt implantation compared with trabeculectomy in 55 
eyes with previous surgery (although mean IOP was similar, significantly lower failure rates were found 56 
with Baerveldt tubes at years 1, 3 and 5).3,4 The primary TVT study is currently investigating the role 57 
of shunts as first line glaucoma surgery.5 These reports support a larger role of aqueous shunts in 58 
glaucoma surgery.3,5,6 59 
However, postoperative complication rates with shunts remain high.4-29 Most early complications 60 
commence with postoperative hypotony resulting in choroidal effusions and/or haemorrhages, 61 
shallow or flat anterior chambers (AC) with or without induced aqueous misdirection, or 62 
maculopathy. With non-valved implants, hypotony usually results from the failure to adequately 63 
restrict aqueous outflow, and several surgical techniques have been introduced to reduce 64 
hypotony-related complications (HRCs). These include two-stage surgery,7 dissolvable ligation 65 
sutures7-11 with or without  tube fenestration,8,10,12,13 intraluminal rip cord (partial-length),14-16 and 66 
intracameral C3F8 gas injection.16-20  67 
In this paper, we demonstrate a technique of Baerveldt shunt implantation in which an occluding 68 
stent is inserted throughout the entire length of the silicone tube, with or without an external 69 
ligature. Postoperatively, the intraluminal outflow resistance can then be systematically adjusted 70 
according to a standardized protocol. We investigated whether this technique can improve 71 
control of intra-ocular pressure (IOP) and reduce the rates of hypotony and hypotony-related 72 
complications. We compared the data to those from the large multi-centre tube-shunt studies4,18,19 73 
as a benchmark of expected outcomes.7,8,10,12-20,40 74 
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METHODS  75 
This was a prospective study of 116 eyes of consecutive patients enrolled between January 2009 76 
and January 2011 from the Glaucoma Unit at Jules-Gonin Eye Hospital, Lausanne, Switzerland. 77 
The surgical methods of Baerveldt (350mm2) tube implantation were standardized prior to 78 
enrolment, and performed by a single experienced glaucoma surgeon (ES). The 3.0 Supramid® 79 
suture (S. Jackson Inc. Alexandria, VA, USA) was used as an intraluminal occluding stent inserted 80 
through the full length of the silicone tube to halt aqueous flow. Postoperatively, outflow was 81 
increased using argon laser suture lysis (if a ligature had been applied intraoperatively) and 82 
through the staged removal of the intraluminal occlusive stent. The postoperative visits and 83 
interventions were determined by a predefined protocol, outlined below. All eyes underwent slit 84 
lamp biomicroscopy, visual acuity (VA), IOP measurements using Goldmann applanation 85 
tonometry, gonioscopy, and dilated fundus examination. Patients with previous aqueous shunt 86 
surgery or encircling band retinal surgery were excluded. Ethical approval was granted by 87 
Commission Cantonale d'Éthique, Vaud, Switzerland and all patients provided written informed 88 
consent. 89 
 90 
Surgical Procedure 91 
Baerveldt shunts were placed superotemporally using a 3-clock-hour conjunctival peritomy. The 92 
tube plate was placed under the bellies of the superior and temporal recti and secured to the 93 
sclera with 9.0 prolene sutures. The Supramid was inserted through the silicone tube until it 94 
reached the distal end, which was trimmed in a bevel up configuration. The stented distal tube 95 
was inserted into the AC through a tight scleral canal, created using a 25-gauge-needle, posterior 96 
to the limbus (figure 1A). Tubes were routinely left unligated. However, if aqueous was seen to 97 
exit at the shunt plate, a 10.0 nylon ligature suture was tied around the proximal stented tube to 98 
halt aqueous flow as a precautionary measure (figure 1A). Processed human pericardium 99 
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(Tutoplast® Pericardium, IOP Ophthalmics, Costa Mesa, USA) was used to cover the tube and a 100 
square 4x4 mm window was created over the proximal portion of the silicone tube, enabling 101 
argon laser suture lysis postoperatively (figures 1B, 1C). The free end of the Supramid was looped 102 
forward, away from the tube plate, tucked under the anterior end of the pericardial patch and 103 
sutured to the sclera using 10.0 nylon to ensure easy access of the occlusive stent post-operatively 104 
(figure 1B). Finally the conjunctiva was closed with 8.0 vicryl sutures, and subconjunctival 105 
cefuroxime and beclamethasone were administered. No viscoelastics were injected into the AC. 106 
Postoperative protocol 107 
Postoperative examinations were performed during study visits on day 1, week 1, 3, 6, month 3, 6 108 
and 12, or more frequently if clinically indicated. Postoperative medications included unpreserved 109 
topical dexamethasone (Dexafree® UD 0.1%) 8 times daily and tapered over 6 weeks and 110 
ofloxacin (Floxal® UD, Bausch and Lomb, Zug, Switzerland) 4 times daily.  111 
Postoperative adjustments to reduce intraluminal outflow resistance and IOP were performed 112 
according to the following time points: 113 
 ≥ 4 weeks postoperatively: argon laser suture lysis (LSL) of the nylon ligature suture 114 
(when present), using a Hoskins lens. 115 
 6-12 weeks postoperatively: partial stent removal (P-SR), the occluding stent was 116 
retracted by 5 mm. This was only performed if IOP remained uncontrolled despite 117 
maximal medications.  118 
 ≥12weeks postoperatively: complete stent removal (C-SR) was performed. In cases of 119 
neovascular glaucoma, uveitis or previous cyclodestructive procedures (risk factors for 120 
hypotony) P-SR was performed as a first procedure and followed by C-SR if required 121 
 Stent removals were not performed when IOP dropped to ≤10 mmHg without glaucoma 122 
medications. 123 
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 124 
Occlusive stent removal   125 
While occlusive stent removal (SR) can be performed at the slit lamp, all study SRs were 126 
performed under topical anaesthesia in the operating room. During this procedure, the anterior 127 
conjunctiva was incised over the Supramid 3.0 suture, which was then either retracted 5.0 mm 128 
and re-sutured to the anterior sclera (P-SR) or completely removed (C-SR). Balanced salt solution 129 
was injected into the AC in eyes with all SRs. Viscoelastic (0.05-0.1mls) was routinely injected 130 
into the AC of eyes undergoing C-SRs. The conjunctiva was sutured using 8.0 vicryl. Tobradex
  131 
(tobramycin, dexamethasone; Alcon, Switzerland) was prescribed 4 times daily and tapered over 4 132 
weeks. IOP was measured at day 1, weeks 1 and 4, following stent removals. 133 
Primary and secondary outcomes 134 
Primary outcomes:  135 
Loss of IOP control, occurring at any time points throughout follow up, was classified as: 136 
Transient hypotony: IOP ≤5 mmHg on two consecutive visits ≥3 weeks and < 6 weeks apart.  137 
Persistent hypotony: IOP ≤5 mmHg on two consecutive visits ≥6 weeks apart. 138 
Transient hypertony: IOP >21 mmHg on two consecutive visits, ≥3 weeks and < 6 weeks apart. 139 
Persistent hypertony: IOP >21 mmHg on two consecutive visits ≥6 weeks apart. 140 
Secondary outcomes:  141 
Failure was defined as: inadequate IOP control (IOP ≤5 mmHg OR >21 mmHg OR <20% 142 
reduction from baseline on 2 consecutive study visits after stent removal (or after 3 months – 143 
where stents were not removed before 6 months, reoperation for glaucoma, loss of light 144 
perception vision, or removal of the implant. 145 
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 Success was defined as IOPs ≤21 mmHg and ≥5 mmHg and >20% reduction in IOP from 146 
baseline on 2 consecutive study visits after stent removal (or after 3 months - where stents were 147 
not removed before 6 months). Reoperation for glaucoma was defined as additional glaucoma 148 
surgery, such as an additional aqueous shunt or cyclodestruction. Post-operative interventions 149 
such as stent removal, needling procedures or laser suture lysis, were not considered glaucoma 150 
reoperations, whether performed in the OR or at the slit lamp. 151 
Complications 152 
Macroscopic hyphema was considered present when >1 mm blood was seen in the AC. 153 
Hypotony related complications were classified as: choroidal effusions/haemorrhage, 154 
shallow/flat AC and hypotony maculopathy. The presence of choroidal effusions and 155 
maculopathy were assessed by routine dilated fundus examination.  156 
Statistical analysis 157 
Analysis was performed using R version 2.15.1. Patients lost to follow-up were censored at their 158 
last visit.  Missing data was assumed to occur at random, and the complete case approach was 159 
adopted. Since some of the variables reported here (e.g. IOP and VA) were not normally 160 
distributed, median and inter-quartile ranges (IQR) were reported. Mean and standard deviation 161 
(SD) were also included to allow comparison with previous studies. 162 
RESULTS 163 
A total of 116 eyes of 112 patients underwent Baerveldt shunt implantation, of these 104 eyes 164 
(90%) completed one-year of follow-up. Of the 12 patients who missed the one-year 165 
appointment, 4 attended later visits and 8 were lost to follow-up (figure 2). Fewer than 15% of 166 
follow-up appointments were missed. 167 
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Patient demographics and surgical outcomes are shown in table 1. Details of postoperative IOP 168 
throughout follow-up are presented in figure 3. The median preoperative IOP was 23 mmHg 169 
(mean 27 mmHg). A marked IOP reduction was noted at all time points after week 1 (figure 3). 170 
The median IOP at 12 months was 12 mmHg (mean 13 mmHg). None of the eyes had IOP ≤5 171 
mmHg on postoperative day 1. Nine eyes (8%) experienced a postoperative IOP ≤5 mmHg at 172 
any study time point. This comprised of one patient with transient hypotony (lasting 3 weeks), 173 
and 8 patients with IOP ≤5 mmHg lasting between 2 and 8 days. Almost all eyes had a gradual 174 
and controlled reduction in IOP (figure 3). None of the eyes developed persistent hypotony. Ten 175 
eyes (9%) had transient hypertony (IOP >21 mmHg), and 3 eyes (3%) had persistent hypertony.  176 
Of the 116 eyes, 38 eyes (33%) underwent tube ligation during shunt implantation. In 8 eyes the 177 
nylon sutures could not be located postoperatively because Tenon’s capsule was too thick. The 178 
remaining 30 eyes underwent LSL on average 6.8 ± 3.1 weeks postoperatively. The median IOP 179 
prior to LSL was 26 mmHg [IQR 19-33 mmHg], which dropped significantly to 14 mmHg [IQR 180 
11-21 mmHg], one week later and remained lower one month later (19 mmHg [IQR 14-22 181 
mmHg]). There were no cases of hypotony or HRCs following LSL. Of the 30 eyes that 182 
underwent LSL, subsequent stent removal was necessary in 25 eyes (8 P-SR; 17 C-SR). Details of 183 
postoperative IOP following LSL, P-SR and C-SR are summarised in table 2 and figure 4. There 184 
were no significant differences between the preoperative and final postoperative IOP of the 185 
ligature stent group versus non-ligature stent group (p=0.60 and p=0.40, respectively). 186 
Stent removals were required in 80% of eyes (n=93). Prior to SR the median IOP was 19 mmHg 187 
[IQR 14-26 mmHg], which reduced to 14 mmHg [IQR 11-20 mmHg] one week later and 188 
remained low after one month (16 mmHg [IQR 12-20 mmHg]). Both C-SR (n=70) and P-SR 189 
(n=23) resulted in significant IOP reduction. Following stent removal 5% (n=5) of eyes required 190 
an increase in medications; only 2 eyes experienced both an increase in IOP and an increase in 191 
glaucoma medications (figure 4). There was no significant difference between IOP reduction 192 
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following C-SR and IOP reduction following P-SR at one week (p=0.65) however at one month 193 
IOP after C-SR was significantly lower than IOP after P-SR (p<0.01). P-SRs did not result in any 194 
HRCs. Early P-SR (3 and 5 weeks) was required in 2 eyes with uncontrolled elevated IOP despite 195 
maximal tolerated medications. One eye required viscoelastic injection into the AC due to low 196 
IOP following C-SR (lasting 2 days). Two eyes required reinsertion of the Supramid stent (via 197 
AC).  198 
The median number of glaucoma medications reduced from 3 [IQR 2-4] preoperatively to 1 [0-2] 199 
postoperatively at year one (figure 3). A significant drop in medications was observed following 200 
SRs, which persisted throughout all subsequent visits. Prior to stent removal the mean number of 201 
glaucoma medications was 3.6 ± 1.5, which reduced to 0.5 ± 1.2 one week later and remained 202 
significantly reduced one month after SR (0.9 ± 1.3). The IOP reduction following stent removal 203 
was not significantly associated with the reduction in number of medications between pre-204 
removal and one-month post-removal (p=0.16, 2 way ANOVA).  205 
Failure occurred in 7 eyes (6%) due to inadequate IOP reduction. However, there were no cases 206 
of persistent hypotony, glaucoma re-operation, or loss of light perception. In the eyes considered 207 
as surgical failure, one eye was lost to follow-up.  In the remaining 6 eyes, median pre-operative 208 
IOP was 15mmHg and postoperatively 13mmHg and mean pre-operative glaucoma medications 209 
was 3.3 and postoperatively 1.2. At month 12, qualified success (with or without medications) 210 
was achieved in 94% (n=98) of eyes and complete success in 32% (n=33) of eyes. 211 
Intraoperative hyphema was observed in 2 patients, and no other intraoperative complications 212 
were observed. Postoperative complications occurred in 11 eyes (9%) and were non-sight 213 
threatening: hyphema (n=1), transient diplopia (n=1), Descemet’s membrane detachment (n=1); 214 
HRCs occurred in 8 eyes: transient hypotony (n=1), shallow AC (n=2) and transient choroidal 215 
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effusions (n=5) (table 3). There were no tube blockages, retractions, erosions or cases of 216 
endophthalmitis.  217 
DISCUSSION 218 
The importance of early flow control following non-valved shunt implantation has previously 219 
been highlighted.8-10,14-16,21,23 This is the first study of aqueous shunts to report IOP data following 220 
full-length intraluminal occlusion and stepwise reductions of flow restriction using laser suture 221 
lysis and partial/complete stent removals, according to requirements (some eyes did not require 222 
stent removal). Complete stent removals were delayed until after 12 weeks of bleb 223 
maturation,7,8,12,32,36 which is in contrast to the traditional use of a rapidly dissolving tie, where 224 
maximal outflow occurs indiscriminately as early as three to six weeks after surgery.  The staged 225 
approach in this study resulted in low rates of hypotony (1%) and overall HRCs (7%), and 226 
consequently the total complication rate was 9%. To our knowledge these are amongst the lowest 227 
reported in the literature (table 3, figure 5).3,8,10,12,13,18-20,22,24,29 228 
In vitro, unligated partial-length Supramid occlusion of Baerveldt shunts does not always provide 229 
sufficient intraluminal resistance to prevent hypotony.23 The full-length occluded shunts used in 230 
our protocol offer additional outflow resistance due both to increased Supramid length and its 231 
passage through the tight intrascleral canal (which obviated the need for ligation in two thirds of 232 
tubes). Postoperatively, scleral squeeze around the stented tube is likely to have gradually relaxed, 233 
allowing aqueous flow into a relatively mature bleb (suggested by the lowering of IOP prior to 234 
stent removal). This delayed and gradual increase in flow may circumvent inflammatory bleb wall 235 
thickening associated with copious early flow, 7,8,12,32,36 and could explain why a hypertensive phase 236 
following removal of flow restriction8,10,12,19,24,32,36 was not observed in study eyes. Further studies 237 
are required to establish whether final IOP is affected by delaying aqueous flow into the maturing 238 
bleb.  239 
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On post-operative day one, none of the study eyes had IOP below 6 mmHg. This lack of 240 
immediate hypotony compares favourably with other techniques.3,8-29  Intraoperative viscoelastic 241 
AC injections were never required during tube implantation. These can cause erratic IOPs in 242 
occluded shunts.3,4,32 Since flow control was central to this protocol, LSL was preferred over a 243 
dissolving tie as this enabled the clinician to determine the need and the timing of resistance 244 
reduction.3,5,8,10,13,18-20 Similarly, partial stent retractions provided an intermediate stage of 245 
resistance reduction when complete removal posed a risk of HRCs (for example in patients with 246 
uveitis, previous cyclodiode, and small eyes). Neither LSL nor P-SR resulted in hypotony related 247 
events. A total of 16% of eyes achieved sufficiently low IOP without requiring stent removal. 248 
Removal of these stents may have resulted in hypotony. 8,12,20,22 Emerick et al reported hypotony 249 
in 25% of eyes following ligature autolysis, where no occluding stent was present.12   250 
Early post-operative complications (predominantly HRCs) using non-valved shunts are largely 251 
preventable using surgical and post-operative strategies,7,19,27 and are not necessarily associated 252 
with surgeon experience.18 The case-mix, prospective protocol and analysis methods of this study 253 
are not unlike those of the ABC study, 18,25 yet here the complication rate was markedly lower  254 
(9% versus 58%); (54% in AVB19; 34% in TVT 3; table 3, figure 5). A major confounder is that 255 
the detection of and reporting of complications varies between studies – not all previous studies 256 
report all complications (figure 5; table 3). However, the mean of each reported HRC was 257 
calculated separately in order to estimate a cumulative HRC rate of 35%3,8,10,12,13,18-20,22,24,29  (table 3; 258 
figure 5). This is substantially greater than the 7% reported here. Transient hypotony (12-259 
25%)8,12,20,22 and persistent hypotony (0-5%)12,18,19,29 were also markedly lower in this study (1% 260 
and 0% respectively).  261 
There were no occurrences of new onset corneal decompensation in this cohort during the first 262 
year of follow-up. Care was taken to leave the intracameral tube short and position it away from 263 
the cornea, and this may have helped to reduce corneal endothelial cell loss. However corneal 264 
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decompensation following prolonged endothelial cell loss is a recognized late-onset complication 265 
of shunt implantation and as such is more likely to feature in reports with longer follow-up.  266 
In contrast to complication rates, the success and failure rates at year one (which are 267 
predominantly IOP determined), were similar to previous studies that included Baerveldt shunts 268 
(figure 6). This supports the notion that given similar ocular characteristics, it is implant 269 
type18,19,29,32,33  and surface area,30,31 rather than surgical technique, that principally determine the 270 
mature bleb characteristics and therefore final IOP.30,31,34,35 At year one, failure rates (6%) were 271 
not dissimilar to those reported with Baerveldt shunts in the TVT and ABC studies (4%3 and 272 
14%18 respectively). The recent large shunt studies report failure using different IOP criteria, 273 
making it difficult to compare, and therefore we have given the full range of outcomes for the 274 
cumulative probability of failure at month 12 (figure 6). Here the most frequently reported failure 275 
criterion of IOP and ≤20% reduction from baseline is shown (figure 6). To facilitate comparison, 276 
the three failure rates at month 12 of the TVT, ABC and AVB studies have been superimposed.  277 
Notably in the 6 eyes that failed within the first year of follow-up, there were no re-operations for 278 
glaucoma. In this subgroup mean IOP reduced by 8% from baseline and there was a 64% 279 
reduction in medications. The reduction in the number of medications due to drug intolerance 280 
was an important preoperative consideration in these patients. 281 
One of the drawbacks of non-valved shunt surgery is the delay in IOP lowering due to flow 282 
restriction. During the early postoperative period (prior to stent removals) the delayed IOP 283 
lowering was not regarded as surgical failure. We therefore presented IOP values and glaucoma 284 
medications for all eyes at all study time points in figure 3 (strip plot). During the first 3 months, 285 
according to clinical requirements, medications were frequently altered, LSL and/or stent 286 
removals were preformed, and hence IOP values across subsequent time points rarely 287 
correspond to the same eye. This prompted the stratification of hypertony (IOP>21mmHg) into 288 
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transient and persistent. Ten eyes (9%) experienced transient hypertony (3-6 weeks) and a further 289 
3 eyes had persistent hypertony (>6 weeks). Thus it is apparent that prolonged periods of high 290 
pressure were a rare phenomenon with this systematic approach. 291 
During stent removals a small incision is made in the anterior conjunctiva to access the free end 292 
of the stent. This added step does increase healthcare costs, but the lower complication rates may 293 
make this approach more acceptable. When resources are scarce, this approach could be reserved 294 
for monocular patients or eyes with advanced disease, vulnerable to visual damage ensuing from 295 
hypotony and its complications.1,10,32 In patients unsuitable for a second postoperative 296 
intervention (e.g, geographical location, expenses, medical reasons) suture removal may be carried 297 
out at the slit lamp. 298 
The outlined surgical methods and postoperative protocol have been described in a manner to 299 
facilitate reproducibility. This method resulted in low rates of hypotony and its related 300 
complications and prevented persistent hypotony in all study eyes. Given the rising rates of 301 
aqueous shunt implantation, continued development of safer implantation techniques and 302 
postoperative treatment strategies are essential.  303 
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Table legends 401 
 402 
Table 1. Summary of the patient demographics and surgical outcomes. (POAG, primary open 403 
angle glaucoma; PEXG, pseudoexfoliation glaucoma; ACG, angle closure glaucoma; PDG, 404 
pigmentary dispersion glaucoma.) 405 
  406 
General 
Eyes, n 116 
Sex M/F, n (%) 63 (54%) / 53 (46%) 
Ethnicity  
 Caucasian  
 Black  
 Latin American 
 Asian 
 Other 
 
 95 
 9 
 4 
 2 
 6 
Mean age, years (± SD) 62.3 years (±22.1) 
Primary glaucoma diagnosis  n (%) 
 Open angle  
 Angle closure  
 Pseudoexfoliation  
 Aphakic 
 Neovascular 
 Congenital 
 Pigmentary dispersion 
 Traumatic 
 Uveitic 
 
 39 (34) 
 18 (16) 
 17 (15) 
 5 (4) 
 11 (9) 
 8 (7) 
 7 (6)  
 6 (5) 
 4 (3) 
Previous incisional surgery, n (%) 
 IOP implantation 
 Deep Sclerectomy 
 Trabeculectomy 
 Express tube 
 Viscocanalostomy 
 Tube 
 
 93 (80) 
 48 (41) 
 32 (28) 
 10 (9) 
 3 (3) 
 1 (1) 
Pre-operative measures,  Median [IQR]  (mean± SD)   
IOP mmHg 23 [18,32] (26.9 ± 11.6) 
Glaucoma medications 3.0 [2,4]  (3.0 ±1.2) 
Visual acuity LogMAR 0.5 [0.2,1.0] (0.9 ±1.0) 
Post-operative measures  Median [IQR]  (mean± SD)  – month 12 
IOP mmHg 12 [10,15] (12.8 ±3.7) 
Glaucoma medications 1 [0,2] (1.1 ±1.3) 
Visual acuity LogMAR 0.4 [0.2,1] (0.7 ±0.7) 
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 407 
 408 
Table 2. Intraocular Pressure (IOP) before and after postoperative adjustments. 409 
  410 
Type of postoperative adjustment 
IOP before adjustment    
Median [IQR] 
IOP 1-week later 
Median [IQR] 
IOP 1-month later  
Median [IQR] 
Ligature laser suture lysis (LSL) only 21 [15, 26] 16 [11, 18] 17.5 [12, 20] 
Partial stent removal  21 [16.5, 30] 14 [11.5, 18.5] 20 [13, 23.5] 
Complete stent removal 19 [14, 24.5] 15 [11, 20] 15 [12, 18.75] 
All stent removals 19 [14, 26] 14 [11, 20] 16 [12, 20] 
Stent removal (without prior LSL) 19 [14.25, 26] 14 [10.25, 20] 16 [12, 20] 
Stent removal (underwent prior LSL) 21 [14.75, 26.5] 16 [11.75, 18.5] 18 [12, 21] 
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 411 
Complication type Systematized 
Occlusion of 
Shunts  (%) 
Studies of Baerveldt shunts:  
Reported complication rates 
  (%) publication reference  
Overall complication rates  9 34,4 38,13 58,1854 19 
Shallow AC 2 11,4  20,18 14,19 1424  
Choroidal effusions 4 16,4 3-9,8 22,10 17-18,12 10,18 13,19 19,22 2324 
Choroidal haemorrhage 0 2 ,4 1,10 0-1,12 2,13 2,18 3,19 3,204,22229 
Hypotonous maculopathy 0 1,4 2,18 524 
Transient Hypotony 1 14-23,8 24-26,12 38,20 2022 
Persistent Hypotony 0 2,4 2,18 229 
Descemet detachment  1 1,4 0,10 1,13 1,19 1,22 3,24 329 
Hyphema 1 2,4 14,10 6-7,12 2,13 6,18 2024  
Diplopia 1 5,4 1-5,12 2,13 5,18 6,19 324  
Macular edema 0 3,4 4,13 2,18 924  
Requirements for AC 
reformation 
0 1,4 010 
Endophthalmitis 0 1,4 0,10 0-1,12 1,13 1,18 0,19 3,22 324 
Tube related complications    
Occlusion 
Malposition 
Erosion 
0 
0 
0 
0 
 
11 19 
2,4 2,10 0-1,12 4,13 9,18 10,19 3,20 522824  
1-2,12 1,13 6,18 2,19 324 
3-5,12 3,13 1,18 3,19 2,20 222 
 
 412 
Table 3. List of complications reported with Baerveldt shunts. 413 
  414 
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 415 
Figure legends 416 
 417 
Figure 1. (A) Intraoperative photograph of fully-stented Baerveldt tube entering the AC through 418 
a tight intrascleral canal (black arrow). Supramid occluding stent can be seen at tube plate (double 419 
black arrow). The 10.0 nylon ligation suture (white arrow) is tied around proximal tube to halt 420 
aqueous egress if detected at tube plate. (B) A photo showing pericardial patch covering tube, 421 
with a posterior window enabling postoperative laser suture lysis (white arrow). The free end of 422 
the Supramid is sutured with 10.0 nylon (black arrow) and tucked under the pericardial patch 423 
near the limbus, to facilitate retraction/removals post-operatively (C) The 10.0 nylon ligation 424 
suture seen through Hoskins lens prior to laser suture lysis 425 
 426 
Figure 2. Flow chart of follow-up achieved at year 1. 427 
Total 
116 
Completed 
year 1 
104 (90%) 
Missed  year 1 
12 (10%) 
Lost to follow 
up 
7 (6%) 
Missed visit 
but came later 
4 (3%) 
Died 
1 (1%) 
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 428 
Figure 3. Summary of postoperative intraocular pressure (IOP) measurements and number of 429 
glaucoma medications throughout follow up. A box and whisker plot summarises IOP values 430 
recorded at each time point, the height of the box represents lower and upper inter-quartile range 431 
(50% of the range), the ends of the whiskers extend to 95% of the range (2.5%-97.5%). The line 432 
bisecting each box represents the median IOP.  Additionally to the right of each box a strip plot 433 
is shown, here with each marker denoting an individuals’ IOP value. These markers are colour 434 
coded where the colour denotes the number of medications. Please note: in strip plots, the same 435 
location at subsequent study points is highly unlikely to correspond to the same eye. The 436 
horizontal red dashed line marks the lower IOP limit associated with hypotony (≤5 mmHg). The 437 
mean IOP and number of medications are also shown beneath this line, at each time point. 438 
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 439 
Figure 4. Summary of the relationship between intraocular pressure (IOP) measures prior to stent 440 
removal (SR) and IOP recorded at 1 month following partial SR (circle) and complete SR 441 
(triangle). The dashed and dotted red lines represent the lower and upper IOP limits defining 442 
hypotony (5mmHg) and hypertony (21mmHg) prior to and following SR. The (solid black) line 443 
of unity representing no change in IOP. Each marker has been colour coded to denote the 444 
change in glaucoma medications following stent removal, with green denoting no change, red 445 
indicates an increase in medications and blue indicates decrease, and the intensity of the colour 446 
denoting the amount of change. 447 
 448 
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 449 
Figure 5. Summary of the complication rates reported in studies of Baerveldt (350) shunts. The 450 
percentage rates of hypotony related complications, persistent hypotony, early, late, and total 451 
number of complications for each study are illustrated. Hypotony related complications include 452 
27 
 
choroidal haemorrhage, choroidal effusion, shallow anterior chamber, hypotony malculopathy 453 
and macular oedema. However since not all studies report all hypotony related complications, a 454 
coloured key has been added to denote which complications are reported in each study. 455 
 456 
 457 
Figure 6. Failure as a function of intraocular pressure (IOP): a summary of the cumulative 458 
probability of failure, at 12 months from this study, is given for 10 different criteria in 1 459 
continuous graph labelled with “SOS”. The three failure rates at month 12 reported in recent 460 
ABC, AVB and TVT studies using Baerveldt shunts have been superimposed. A dotted line has 461 
been used to connect the reported values  462 
 463 
